SINOVAC - NEW! - MAKE 15-90 TIMES YOUR MONEY - 500 Beiträge pro Seite
eröffnet am 11.09.05 12:39:21 von
neuester Beitrag 13.09.05 13:34:38 von
neuester Beitrag 13.09.05 13:34:38 von
Beiträge: 135
ID: 1.006.109
ID: 1.006.109
Aufrufe heute: 0
Gesamt: 2.426
Gesamt: 2.426
Aktive User: 0
ISIN: AGP8696W1045 · WKN: 789125
5,7500
EUR
+0,88 %
+0,0500 EUR
Letzter Kurs 22.02.19 Tradegate
Neuigkeiten
21.02.24 · Business Wire (engl.)  |
18.01.24 · Business Wire (dt.) |
18.01.24 · Business Wire (engl.) |
11.09.23 · Business Wire (dt.) |
11.09.23 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 4,7450 | +35,57 | |
| 0,5250 | +19,08 | |
| 5,8900 | +17,80 | |
| 1,9700 | +15,20 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,7000 | -13,71 | |
| 3,0400 | -19,95 | |
| 1,9500 | -25,14 | |
| 1,6052 | -30,21 | |
| 0,5121 | -30,80 |
Feedback
http://tinyurl.com/73ojh
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
DIE VOGELGRIPPE KOMMT!
http://tinyurl.com/aupjz
http://tinyurl.com/7rlgv
http://tinyurl.com/8ek6m
http://tinyurl.com/a582d
http://tinyurl.com/c2w2m
http://tinyurl.com/afp73" target="_blank" rel="nofollow ugc noopener">
http://tinyurl.com/afp73
http://tinyurl.com/9ck8l
http://tinyurl.com/d4kgh
http://tinyurl.com/aupjz
http://tinyurl.com/7rlgv
http://tinyurl.com/8ek6m
http://tinyurl.com/a582d
http://tinyurl.com/c2w2m
http://tinyurl.com/afp73" target="_blank" rel="nofollow ugc noopener">
http://tinyurl.com/afp73
http://tinyurl.com/9ck8l
http://tinyurl.com/d4kgh
- DAS VOGELGRIPPE-VIRUS EXISTIERT NOCH NICHT IN DER FORM, DASS ES SICH RASCH VON MENSCH ZU MENSCH AUSBREITET - EXPERTEN GEHEN ABER DAVON AUS, DASS SICH DAS VIRUS MIT DEM GRIPPEVIRUS VERBINDET - SINOVAC WAR DIE ERSTE FIRMA, WELCHE EINEN IMPFSTOFF GEGEN SARS ENTWICKELTE - SINOVAC WIRD AUCH DIE ERSTE FIRMA SEIN, WELCHE EINEN IMPFSTOFF GEGEN DAS MUTIERTE VOGELGRIPPEVIRUS AUF DEN MARKT BRINGT !
http://tinyurl.com/dr67h
http://tinyurl.com/dr67h
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
Trading Spotlight
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, " this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. " bird flu" ). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE " SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, " this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. " bird flu" ). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE " SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Chart-Analyst: Bullish Signals
MACD generates bullish signals:
1. Positive divergence
2. Bullish moving average crossover
3. Bullish centerline crossover
http://tinyurl.com/aacqc Hinweis: Ende 2003 Ausbruch SARS!
MACD generates bullish signals:
1. Positive divergence
2. Bullish moving average crossover
3. Bullish centerline crossover
http://tinyurl.com/aacqc Hinweis: Ende 2003 Ausbruch SARS!
ANGANG 2003 AUSBRUCH SARS - WIEDERHOLT SICH DAS SZENARIO MIT DER VOGELGRIPPE?
http://tinyurl.com/2ulu2
http://tinyurl.com/2ulu2
http://tinyurl.com/73ojh
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and invest
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and invest
- DAS VOGELGRIPPE-VIRUS EXISTIERT NOCH NICHT IN DER FORM, DASS ES SICH RASCH VON MENSCH ZU MENSCH AUSBREITET - EXPERTEN GEHEN ABER DAVON AUS, DASS SICH DAS VIRUS MIT DEM GRIPPEVIRUS VERBINDET - SINOVAC WAR DIE ERSTE FIRMA, WELCHE EINEN IMPFSTOFF GEGEN SARS ENTWICKELTE - SINOVAC WIRD AUCH DIE ERSTE FIRMA SEIN, WELCHE EINEN IMPFSTOFF GEGEN DAS MUTIERTE VOGELGRIPPEVIRUS AUF DEN MARKT BRINGT !
http://tinyurl.com/dr67h
http://tinyurl.com/dr67h
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, " this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. " bird flu" ). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE " SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, " this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. " bird flu" ). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE " SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Chart-Analyst: Bullish Signals
MACD generates bullish signals:
1. Positive divergence
2. Bullish moving average crossover
3. Bullish centerline crossover
http://tinyurl.com/aacqc Hinweis: Ende 2003 Ausbruch SARS!
MACD generates bullish signals:
1. Positive divergence
2. Bullish moving average crossover
3. Bullish centerline crossover
http://tinyurl.com/aacqc Hinweis: Ende 2003 Ausbruch SARS!
ANFANG 2003 AUSBRUCH SARS - WIEDERHOLT SICH DAS SZENARIO MIT DER VOGELGRIPPE?
http://tinyurl.com/2ulu2
http://tinyurl.com/2ulu2
http://tinyurl.com/73ojh
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
- DAS VOGELGRIPPE-VIRUS EXISTIERT NOCH NICHT IN DER FORM, DASS ES SICH RASCH VON MENSCH ZU MENSCH AUSBREITET - EXPERTEN GEHEN ABER DAVON AUS, DASS SICH DAS VIRUS MIT DEM GRIPPEVIRUS VERBINDET - SINOVAC WAR DIE ERSTE FIRMA, WELCHE EINEN IMPFSTOFF GEGEN SARS ENTWICKELTE - SINOVAC WIRD AUCH DIE ERSTE FIRMA SEIN, WELCHE EINEN IMPFSTOFF GEGEN DAS MUTIERTE VOGELGRIPPEVIRUS AUF DEN MARKT BRINGT !
http://tinyurl.com/dr67h
http://tinyurl.com/dr67h
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, " this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. " bird flu" ). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE " SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, " this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. " bird flu" ). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE " SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Chart-Analyst: Bullish Signals
MACD generates bullish signals:
1. Positive divergence
2. Bullish moving average crossover
3. Bullish centerline crossover
http://tinyurl.com/aacqc Hinweis: Ende 2003 Ausbruch SARS!
MACD generates bullish signals:
1. Positive divergence
2. Bullish moving average crossover
3. Bullish centerline crossover
http://tinyurl.com/aacqc Hinweis: Ende 2003 Ausbruch SARS!
Gallery View:
http://tinyurl.com/dfbyu
http://tinyurl.com/dfbyu
ANFANG 2003 AUSBRUCH SARS - WIEDERHOLT SICH DAS SZENARIO MIT DER VOGELGRIPPE?
http://tinyurl.com/73ojh
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
DIE VOGELGRIPPE KOMMT!
http://tinyurl.com/aupjz
http://tinyurl.com/7rlgv
http://tinyurl.com/8ek6m
http://tinyurl.com/a582d
http://tinyurl.com/c2w2m
http://tinyurl.com/afp73
http://tinyurl.com/9ck8l
http://tinyurl.com/d4kgh
DAS THEMA WIRD IN DEN MEDIEN NOCH ZURÜCKGEHALTEN, WEIL DIE POLITIKER ANGST VOR EINER MASSENPANIK HABEN. WAS GLAUBST DU PASSIERT, WENN SCHON NUR ERSTE GERÜCHTE IM UMFLAUF SIND, DAS VIRUS KÖNNTE SICH MIT DEM GRIPPEVIRUS VERMISCHT HABEN. OBIGE LINKS ENTHALTEN AUCH DIE MEINUNG DER WHO (Weltgesundheitsorganisation)!
http://tinyurl.com/aupjz
http://tinyurl.com/7rlgv
http://tinyurl.com/8ek6m
http://tinyurl.com/a582d
http://tinyurl.com/c2w2m
http://tinyurl.com/afp73
http://tinyurl.com/9ck8l
http://tinyurl.com/d4kgh
DAS THEMA WIRD IN DEN MEDIEN NOCH ZURÜCKGEHALTEN, WEIL DIE POLITIKER ANGST VOR EINER MASSENPANIK HABEN. WAS GLAUBST DU PASSIERT, WENN SCHON NUR ERSTE GERÜCHTE IM UMFLAUF SIND, DAS VIRUS KÖNNTE SICH MIT DEM GRIPPEVIRUS VERMISCHT HABEN. OBIGE LINKS ENTHALTEN AUCH DIE MEINUNG DER WHO (Weltgesundheitsorganisation)!
Ausbruch Vogelgrippe Monat August!
Siehe Karte unter nachfolgendem Link:
http://tinyurl.com/8z552
Hinweis: Die Forscher sind sehr besorgt darüber, dass sich das Virus sogar in den Sommermonaten so schnell verbreitet. Und in Vietnam sind sogar bereits Fälle aufgetreten, wo eine Mensch zu Mensch - Übertragung nicht auszuschliessen ist.
Siehe Karte unter nachfolgendem Link:
http://tinyurl.com/8z552
Hinweis: Die Forscher sind sehr besorgt darüber, dass sich das Virus sogar in den Sommermonaten so schnell verbreitet. Und in Vietnam sind sogar bereits Fälle aufgetreten, wo eine Mensch zu Mensch - Übertragung nicht auszuschliessen ist.
Mit Sinovac investiert man in ein Unternehmen, dass im Wachstumsmarkt China hervorragend positioniert ist und von der Regierung unterstützt wird. Sinovac hat eine breite Produktepipeline.
Auch ohne Vogelgrippe hat die Aktie blendende Zukunftsaussichten.
Auch ohne Vogelgrippe hat die Aktie blendende Zukunftsaussichten.
" Wir erwarten eine verheerende Influenza-Pandemie innerhalb der kommenden Monate in Deutschland" , verkündete kürzlich Adel Massaad, Leiter des deutschen Instituts für Gesundheitsaufklärung (IFGA).
Quelle: http://tinyurl.com/d4kgh
Quelle: http://tinyurl.com/d4kgh
http://tinyurl.com/73ojh
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
- DAS VOGELGRIPPE-VIRUS EXISTIERT NOCH NICHT IN DER FORM, DASS ES SICH RASCH VON MENSCH ZU MENSCH AUSBREITET - EXPERTEN GEHEN ABER DAVON AUS, DASS SICH DAS VIRUS MIT DEM GRIPPEVIRUS VERBINDET - SINOVAC WAR DIE ERSTE FIRMA, WELCHE EINEN IMPFSTOFF GEGEN SARS ENTWICKELTE - SINOVAC WIRD AUCH DIE ERSTE FIRMA SEIN, WELCHE EINEN IMPFSTOFF GEGEN DAS MUTIERTE VOGELGRIPPEVIRUS AUF DEN MARKT BRINGT !
http://tinyurl.com/dr67h
http://tinyurl.com/dr67h
Ausbruch Vogelgrippe Monat Juli
Siehe Karte unter folgendem Link:
http://tinyurl.com/bab5y
Ausbruch Vogelgrippe Monat August!
Siehe Karte unter nachfolgendem Link:
http://tinyurl.com/8z552
Hinweis: Die Forscher sind sehr besorgt darüber, dass sich das Virus sogar in den Sommermonaten so schnell verbreitet. Und in Vietnam sind sogar bereits Fälle aufgetreten, wo eine Mensch zu Mensch - Übertragung nicht auszuschliessen ist.
Siehe Karte unter folgendem Link:
http://tinyurl.com/bab5y
Ausbruch Vogelgrippe Monat August!
Siehe Karte unter nachfolgendem Link:
http://tinyurl.com/8z552
Hinweis: Die Forscher sind sehr besorgt darüber, dass sich das Virus sogar in den Sommermonaten so schnell verbreitet. Und in Vietnam sind sogar bereits Fälle aufgetreten, wo eine Mensch zu Mensch - Übertragung nicht auszuschliessen ist.
" Wir erwarten eine verheerende Influenza-Pandemie innerhalb der kommenden Monate in Deutschland" , verkündete kürzlich Adel Massaad, Leiter des deutschen Instituts für Gesundheitsaufklärung (IFGA).
Quelle: http://tinyurl.com/d4kgh
Hoffen wir, dass die Politiker vernüftig genug sind, die entsprechenden Vorsichtsmassnahmen einzuleiten.
Was Sinovac betrifft - es reicht, wenn die Medien anfangen stärker über die Vogelgrippe zu berichten. Für einen Hype reichen schon Gerüchte.
Hinweis: Von Oktober bis März ist Grippezeit. Das Kerngeschäft von Sinovac sind Impfungen!
willste heute wohl mit allen mitteln auf platz 1 in den top stocks ???? 
regnets bei dir ???
regnets bei dir ???
jetzt mußt du noch 10.000x draufklicken, dann wirst du auch erster bei den meistgelesenen beiträgen
Welche Drogen nimmst Du?
echt, sowas durchgeknalltes. meinste deine gehirnwäsche hilft? bei mir nicht.
@Rambold_Toni
Es regnet tatsächlich.
Es regnet tatsächlich.
@Newbee
Mmmmhhh - deine Hydroflo ist übrigens noch interessant - leider ist die Aktie bereits ganz schön gestiegen.
Mmmmhhh - deine Hydroflo ist übrigens noch interessant - leider ist die Aktie bereits ganz schön gestiegen.
@all
Gerade ist wieder ne neue Meldung reingekommen:
Fourth Fatal Human H5N1 Bird Flu in Jakarta Indonesia
http://tinyurl.com/afp73
PS: Ihr könnt ja viel schreiben - aber die ganzen News, auf die sich die Quellenangaben beziehen - hab ich nicht selber geschrieben.
Gerade ist wieder ne neue Meldung reingekommen:
Fourth Fatal Human H5N1 Bird Flu in Jakarta Indonesia
http://tinyurl.com/afp73
PS: Ihr könnt ja viel schreiben - aber die ganzen News, auf die sich die Quellenangaben beziehen - hab ich nicht selber geschrieben.
http://tinyurl.com/afp73
Fourth Human H5N1 Bird Flu Fatality in Jakarta Indonesia
Recombinomics Commentary
September 11, 2005
The woman, 37, died on Saturday night in a hospital in south Jakarta, after suffering from pneumonia and flu-like respiratory problems since Sept. 6.
"We had taken samples for tests and one showed it was positive (for the H5N1 strain)," Health Minister Siti Fadillah Supari told El Shinta radio, adding that more tests were being done.
The above information on Indonesia`s fourth H5N1 bird flu fatality is cause for concern. Like the H5N1 cases in Cambodia, all confirmed cases have proved to be fatal. This high fatality rate is similar to south Vietnam. Recent sequence data has shown that H5N1 in 2004 was virtually identical in Vietnam, Thailand, Laos, and Malaysia. In 2005, these similarities were clear in southern Vietnam, Cambodia, and Thailand.
The fourth fatality in Indonesia is again in Jakarta, where there have also been reports of H5N1 in swine. The swine sequences were similar to H5N1 in Yunnan China. The three earlier cases formed a familiar cluster with a bimodal distribution of onset dates, provide solid evidence for human-to-human transmission. This transmission profile matches earlier familial clusters in Thailand, Cambodia, and Vietnam.
Sequence data from the earlier cluster would be useful. Earlier H5N1 isolates from Indonesia were the Z genotype, but there are regional differences and early sequences from Indonesia are distinct from those for fatal cases in Vietnam, Thailand, and Cambodia.
The H5N1 source of the earlier cluster in Tangerang, a Jakarta suburb was not conclusively determined. The closest sample that was a H5N1 positive was found in the bottom of a neighbor`s pet birdcage.
Fourth Human H5N1 Bird Flu Fatality in Jakarta Indonesia
Recombinomics Commentary
September 11, 2005
The woman, 37, died on Saturday night in a hospital in south Jakarta, after suffering from pneumonia and flu-like respiratory problems since Sept. 6.
"We had taken samples for tests and one showed it was positive (for the H5N1 strain)," Health Minister Siti Fadillah Supari told El Shinta radio, adding that more tests were being done.
The above information on Indonesia`s fourth H5N1 bird flu fatality is cause for concern. Like the H5N1 cases in Cambodia, all confirmed cases have proved to be fatal. This high fatality rate is similar to south Vietnam. Recent sequence data has shown that H5N1 in 2004 was virtually identical in Vietnam, Thailand, Laos, and Malaysia. In 2005, these similarities were clear in southern Vietnam, Cambodia, and Thailand.
The fourth fatality in Indonesia is again in Jakarta, where there have also been reports of H5N1 in swine. The swine sequences were similar to H5N1 in Yunnan China. The three earlier cases formed a familiar cluster with a bimodal distribution of onset dates, provide solid evidence for human-to-human transmission. This transmission profile matches earlier familial clusters in Thailand, Cambodia, and Vietnam.
Sequence data from the earlier cluster would be useful. Earlier H5N1 isolates from Indonesia were the Z genotype, but there are regional differences and early sequences from Indonesia are distinct from those for fatal cases in Vietnam, Thailand, and Cambodia.
The H5N1 source of the earlier cluster in Tangerang, a Jakarta suburb was not conclusively determined. The closest sample that was a H5N1 positive was found in the bottom of a neighbor`s pet birdcage.
tja, bin ja auch dabei, denke wir haben hier noch ne großartige entwicklung vor uns
@Rambold_Toni
Man kann übrigens nicht einfach 1`000 Mal klicken, um unter den meistgelesenen Beiträgen zu landen. WO kontrolliert das via IP-Adresse.
Man kann übrigens nicht einfach 1`000 Mal klicken, um unter den meistgelesenen Beiträgen zu landen. WO kontrolliert das via IP-Adresse.
@promailer
Zuerst wurden nur Menschen infiziert, welche direkt mit Hühnern zu tun hatten. Jetzt wird das Virus schon von Säugetieren auf den Menschen übertragen.
- Denk ich mir das etwa aus?
http://tinyurl.com/afp73
Zuerst wurden nur Menschen infiziert, welche direkt mit Hühnern zu tun hatten. Jetzt wird das Virus schon von Säugetieren auf den Menschen übertragen.
- Denk ich mir das etwa aus?
http://tinyurl.com/afp73
Schaut euch doch die News an!
In der Schweiz haben die Behörden noch vor zwei Monaten verlauten lassen, dass bei uns die Hühner ja nicht auf den Strassen herumlaufen. Inzwischen ist dieser arrogante Tonfall auch verschwunden. Die Medien berichten zwar immer noch sehr verhalten und die Behörden spielen die Gefahr herunter - aber plötzlich taucht das Thema immer wieder auf. Und lustig macht sich inzwischen auch niemand mehr darüber.
In Deutschland hat die Regierung einen Notfallplan entwickelt. Und auch England hat einen solchen Plan - genau wie die USA. - Weshalb wohl?
Hinweis: Hab heute versucht die Aktie etwas bekannter zu machen. Wenn ihr euch durch den Thread klickt, werdet ihr feststellen, dass ich grösstenteilt nur Informationen mit Quellenangaben poste. Ich gebe hier nicht nur einfach meine Meinung zum Besten.
Grüsse
notebook
In der Schweiz haben die Behörden noch vor zwei Monaten verlauten lassen, dass bei uns die Hühner ja nicht auf den Strassen herumlaufen. Inzwischen ist dieser arrogante Tonfall auch verschwunden. Die Medien berichten zwar immer noch sehr verhalten und die Behörden spielen die Gefahr herunter - aber plötzlich taucht das Thema immer wieder auf. Und lustig macht sich inzwischen auch niemand mehr darüber.
In Deutschland hat die Regierung einen Notfallplan entwickelt. Und auch England hat einen solchen Plan - genau wie die USA. - Weshalb wohl?
Hinweis: Hab heute versucht die Aktie etwas bekannter zu machen. Wenn ihr euch durch den Thread klickt, werdet ihr feststellen, dass ich grösstenteilt nur Informationen mit Quellenangaben poste. Ich gebe hier nicht nur einfach meine Meinung zum Besten.
Grüsse
notebook
@notebook
du hast leider bei deiner thread-eröffnung vergessen, im feld "Aktie, WKN" die Wertpapierkennnummer anzugeben.
jetzt wirds wohl nix mit den Top Hot Stocks.
bleibt dir nix anderes übrig, als einen neuen thread aufzumachen.
du hast leider bei deiner thread-eröffnung vergessen, im feld "Aktie, WKN" die Wertpapierkennnummer anzugeben.
jetzt wirds wohl nix mit den Top Hot Stocks.
bleibt dir nix anderes übrig, als einen neuen thread aufzumachen.
The three earlier cases formed a familiar cluster with a bimodal distribution of onset dates, provide solid evidence for human-to-human transmission.
http://tinyurl.com/afp73
Die Meldung ist gerade heute reingekommen. Das ist übrigens nicht der erste Verdacht betreffend einer Mensch-zu-Mensch-Übertragung.
http://tinyurl.com/afp73
Die Meldung ist gerade heute reingekommen. Das ist übrigens nicht der erste Verdacht betreffend einer Mensch-zu-Mensch-Übertragung.
@Rambold_Toni
Es gibt noch andere Threads zu Sinovac.
Noch was. Es ist zwar markaber, aber ohne Investoren würde es ja auch keinen Impfstoff geben. Und eines ist sicher, wenn sich die Vogelgrippe ausbreitet, dürften wohl nur noch wenige Aktien performen. Die aber dann umso mehr.
Es gibt noch andere Threads zu Sinovac.
Noch was. Es ist zwar markaber, aber ohne Investoren würde es ja auch keinen Impfstoff geben. Und eines ist sicher, wenn sich die Vogelgrippe ausbreitet, dürften wohl nur noch wenige Aktien performen. Die aber dann umso mehr.
Den Thread zu eröffnen war keine grosse Sache. Nochmals - du kannst nicht 1`000 Mal posten und draufklicken. Das wird vie IP-Adresse kontrolliert.
Denke der Thread wird gelesen, weil ich nicht meine Meinung poste, sondern auf Dritte verweise. Zudem überzeugt Sinovac auch sonst mit ihrer Produktepipeline und ist deshalb für viele Leser nichts Neues.
Aber dass die Bedrohung der Vogelgrippe noch nicht ins Bewusstsein gekommen ist, hat nur damit zu tun, dass dieses Thema gemieden wird.
Tja - das ist das Problem bei Aktien. Wären sich alle der Gefahr bewusst, wäre Sinovac nicht mehr so günstig zu haben.
Denke der Thread wird gelesen, weil ich nicht meine Meinung poste, sondern auf Dritte verweise. Zudem überzeugt Sinovac auch sonst mit ihrer Produktepipeline und ist deshalb für viele Leser nichts Neues.
Aber dass die Bedrohung der Vogelgrippe noch nicht ins Bewusstsein gekommen ist, hat nur damit zu tun, dass dieses Thema gemieden wird.
Tja - das ist das Problem bei Aktien. Wären sich alle der Gefahr bewusst, wäre Sinovac nicht mehr so günstig zu haben.
http://tinyurl.com/73ojh
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
...mal merk...
Verdachtsfälle einer Mensch-zu-Mensch-Übertragung erhärten sich.
http://www.recombinomics.com/News/09110502/H5N1_Indonesia_Ne…
H5N1 False Negatives in Jakarta Indonesia Raise Concerns
Recombinomics Commentary
September 11, 2005
The minister said that one of the blood samples taken from the woman before she died tested positive for avian influenza virus but others were negative.
The above comments suggest the recent fatality (37F) will test positive for H5N1 in additional tests in Hong Kong. However, the negative tests described above again raise concerns about the use of negative lab data to excluded patients with bird flu symptoms, especially when the cases are fatal. These exclusions underestimate the true extent of the disease and create very long delays in inclusion in official case lists, which could seriously compromise intervention efforts.
The earlier familial cluster in the nearby suburb of Tangergang is a good example. Three fatal cases were initially diagnosed as bacterial pneumonia when H5N1 test were negative or equivocal. Only the father (38M) was confirmed to be H5N1 positive by PCR. He developed symptoms on July 2, died July 12, and was officially announced by the WHO on July 21. The index case, his 8 year-old daughter developed symptoms on June 24 and died July 14. The official announcement of her positive lab results for H5 antibody was made on July 29. The first family member to die was the 1 year old daughter who developed symptoms on June 29 and died July 9. There has yet to be an announcement that she was positive in lab tests.
The clustering of the dates of the fatal pneumonias leaves little doubt that all three family members died of bird flu. The gap in onset dates also string suggests the index case infected the two family members. The clustering and likely human-to-human transmission is frequent. Virtually all familial clusters in Vietnam, Thailand, and Cambodia show the same pattern as the Indonesian cluster. Most of the members in the cluster die and although false negatives are common, at least one family member is H5N1 laboratory confirmed and there is a 5-10 gap between onset date of the index case and additional family members.
The latest case in Indonesia follows the pattern in northern Vietnam which generated geographical clusters. All four cases in Indonesia were in the vicinity of Jakarta, as were three additional suspect cases, which were not reported as confirmed in media reports. The clustering of the four cases with reported lab confirmations is cause for concern and raises questions about negative results in the other suspect cases, especially the cook who died. Retrospective diagnosis of fatal cases are especially difficult because PCR results require collection of appropriate samples at the appropriate time, and serological detection may be limited to samples collected weeks after diseases onset dates.
The fourth laboratory confirmed case in the same geographical location in Indonesia is cause for concern.
http://www.recombinomics.com/News/09110502/H5N1_Indonesia_Ne…
H5N1 False Negatives in Jakarta Indonesia Raise Concerns
Recombinomics Commentary
September 11, 2005
The minister said that one of the blood samples taken from the woman before she died tested positive for avian influenza virus but others were negative.
The above comments suggest the recent fatality (37F) will test positive for H5N1 in additional tests in Hong Kong. However, the negative tests described above again raise concerns about the use of negative lab data to excluded patients with bird flu symptoms, especially when the cases are fatal. These exclusions underestimate the true extent of the disease and create very long delays in inclusion in official case lists, which could seriously compromise intervention efforts.
The earlier familial cluster in the nearby suburb of Tangergang is a good example. Three fatal cases were initially diagnosed as bacterial pneumonia when H5N1 test were negative or equivocal. Only the father (38M) was confirmed to be H5N1 positive by PCR. He developed symptoms on July 2, died July 12, and was officially announced by the WHO on July 21. The index case, his 8 year-old daughter developed symptoms on June 24 and died July 14. The official announcement of her positive lab results for H5 antibody was made on July 29. The first family member to die was the 1 year old daughter who developed symptoms on June 29 and died July 9. There has yet to be an announcement that she was positive in lab tests.
The clustering of the dates of the fatal pneumonias leaves little doubt that all three family members died of bird flu. The gap in onset dates also string suggests the index case infected the two family members. The clustering and likely human-to-human transmission is frequent. Virtually all familial clusters in Vietnam, Thailand, and Cambodia show the same pattern as the Indonesian cluster. Most of the members in the cluster die and although false negatives are common, at least one family member is H5N1 laboratory confirmed and there is a 5-10 gap between onset date of the index case and additional family members.
The latest case in Indonesia follows the pattern in northern Vietnam which generated geographical clusters. All four cases in Indonesia were in the vicinity of Jakarta, as were three additional suspect cases, which were not reported as confirmed in media reports. The clustering of the four cases with reported lab confirmations is cause for concern and raises questions about negative results in the other suspect cases, especially the cook who died. Retrospective diagnosis of fatal cases are especially difficult because PCR results require collection of appropriate samples at the appropriate time, and serological detection may be limited to samples collected weeks after diseases onset dates.
The fourth laboratory confirmed case in the same geographical location in Indonesia is cause for concern.
@promailer
"tja, bin ja auch dabei, denke wir haben hier noch ne großartige entwicklung vor uns"
Um ehrlich zu sein, spekulierte ich ein wenig auf einen möglichen Hype, der auf Gerüchten basiert. Inzwischen sind ja alle Wissenschaftler vom Ausbruch überzeugt. Denke ohne Investitionen gäbs ja auch keine Impfstoffe. Aber erfreulich oder gar grossartig ist diese Entwicklung nicht. (Weiss natürlich, dass sich bei dir "grossartig" auf die Aktie bezieht).
Wenn du dir die neusten Meldungen durchliesst, wird das Virus noch schneller da sein, als uns lieb ist.
"tja, bin ja auch dabei, denke wir haben hier noch ne großartige entwicklung vor uns"
Um ehrlich zu sein, spekulierte ich ein wenig auf einen möglichen Hype, der auf Gerüchten basiert. Inzwischen sind ja alle Wissenschaftler vom Ausbruch überzeugt. Denke ohne Investitionen gäbs ja auch keine Impfstoffe. Aber erfreulich oder gar grossartig ist diese Entwicklung nicht. (Weiss natürlich, dass sich bei dir "grossartig" auf die Aktie bezieht).
Wenn du dir die neusten Meldungen durchliesst, wird das Virus noch schneller da sein, als uns lieb ist.
[posting]17.857.813 von notebook am 11.09.05 17:30:24[/posting]Vogelgrippe - da musst du Tamilflu (hat nichts mit Tamilen zu tun :laugh
von Roche posten, die arbeiten momentan 3-schichtig - Umsatz mit diesem Produkt wird wohl über 1 Mrd. CHF ausmachen im 2005 !
Kauft ROG-Titel !!
Charly
von Roche posten, die arbeiten momentan 3-schichtig - Umsatz mit diesem Produkt wird wohl über 1 Mrd. CHF ausmachen im 2005 !Kauft ROG-Titel !!
Charly
@Charly_2
Folgendes:
Sinovac ist Ende 2003 von 0.2 Dollar auf 6 Dollar gestiegen. Als sie dann ein Mittel hatten und alle KAUFEN schrien, ist die Aktie wieder gesunken!
1. Es kann noch gar keinen Impfstoff geben, weil es auch das Virus in der Endform noch nicht gibt. - Soviel zu Tamiflu.
2. H5N1 verändert sich ständig und wird resistenter.
3. Was die WHO (Weltgesundheitsorganisation) beunruhigt, ist, dass sich das Vogelgrippevirus mit dem menschlichen Grippevirus verbindet. Dafür gibt es noch keinen Impfstoff - weil es wie gesagt das Virus noch nicht gibt.
4. Sinovac hat bei SARS entgegen allen Erwartungen als erste Unternehmung ein Mittel auf den Markt gebracht. Dies war möglich, weil in China die Zulassungen sehr schnell erteilt werden , wenn es darauf ankommt. - Die haben damals das Virus direkt am Menschen getestet und gewisse Schritte einfach übersprungen.
5. Natürlich wird es einen Konkurrenzkampf geben. Es ist anzunehmen, dass eine Firma alleine nicht in der Lage sein wird, die Welt mit Impfstoffen zu versorgen.
6. Man könnte auch Roche-Aktien kaufen. Zurzeit ist Tamiflu vielversprechend. Allerdings ist Tamiflu für Roche nur ein Nebengleis. Ist ja ne riesige Firma. Es ist daher nicht anzunehmen, dass eine Vogelgrippe bei Roche einen Vervielfacher auslösen wird.
7. China ist ein riesiger Markt.
8. Die meisten Menschen wissen noch nicht einmal, dass es eine Pandemie geben könnte. Aber die Biotechs wissen das schon lange. Wenn die Vogelgrippe ausbrechen wird, gibt es einen Hype bei Biotechs, welche Impfstoffe gegen die Vogelgrippe entwickeln. Sobald ein Impfstoff da ist, werden vermutlich alle sagen - jetzt kaufen. Gerade dann ist aber der Zeitpunkt um auszusteigen. - War bei SARS auch so. Aktie ist von 0.2 auf 6 Dollar gestiegen. Im März 2004 haben dann alle " kaufen" geschrien. Dann gings aber wieder runter mit dem Kurs.
Buy on bad news, sell on good news. Das ist ja der Witz der Sache. Wenn sich alle der Gefahr einer Pandemie bewusst wären, könnte man Sinovac nicht zum Kurs von 3.5$ kaufen.
Folgendes:
Sinovac ist Ende 2003 von 0.2 Dollar auf 6 Dollar gestiegen. Als sie dann ein Mittel hatten und alle KAUFEN schrien, ist die Aktie wieder gesunken!
1. Es kann noch gar keinen Impfstoff geben, weil es auch das Virus in der Endform noch nicht gibt. - Soviel zu Tamiflu.
2. H5N1 verändert sich ständig und wird resistenter.
3. Was die WHO (Weltgesundheitsorganisation) beunruhigt, ist, dass sich das Vogelgrippevirus mit dem menschlichen Grippevirus verbindet. Dafür gibt es noch keinen Impfstoff - weil es wie gesagt das Virus noch nicht gibt.
4. Sinovac hat bei SARS entgegen allen Erwartungen als erste Unternehmung ein Mittel auf den Markt gebracht. Dies war möglich, weil in China die Zulassungen sehr schnell erteilt werden , wenn es darauf ankommt. - Die haben damals das Virus direkt am Menschen getestet und gewisse Schritte einfach übersprungen.
5. Natürlich wird es einen Konkurrenzkampf geben. Es ist anzunehmen, dass eine Firma alleine nicht in der Lage sein wird, die Welt mit Impfstoffen zu versorgen.
6. Man könnte auch Roche-Aktien kaufen. Zurzeit ist Tamiflu vielversprechend. Allerdings ist Tamiflu für Roche nur ein Nebengleis. Ist ja ne riesige Firma. Es ist daher nicht anzunehmen, dass eine Vogelgrippe bei Roche einen Vervielfacher auslösen wird.
7. China ist ein riesiger Markt.
8. Die meisten Menschen wissen noch nicht einmal, dass es eine Pandemie geben könnte. Aber die Biotechs wissen das schon lange. Wenn die Vogelgrippe ausbrechen wird, gibt es einen Hype bei Biotechs, welche Impfstoffe gegen die Vogelgrippe entwickeln. Sobald ein Impfstoff da ist, werden vermutlich alle sagen - jetzt kaufen. Gerade dann ist aber der Zeitpunkt um auszusteigen. - War bei SARS auch so. Aktie ist von 0.2 auf 6 Dollar gestiegen. Im März 2004 haben dann alle " kaufen" geschrien. Dann gings aber wieder runter mit dem Kurs.
Buy on bad news, sell on good news. Das ist ja der Witz der Sache. Wenn sich alle der Gefahr einer Pandemie bewusst wären, könnte man Sinovac nicht zum Kurs von 3.5$ kaufen.
@Charly_2
Dein Hinweis ist berechtigt. Ich denke aber, dass bei einem Hype die " Kleinen" immer am stärksten profitieren. Es wird niemand mit Bestimmtheit sagen können, wer das Rennen macht. Bei SARS ist Sinovac von 0.2 auf 6 Dollar gestiegen. Als dann der wirksame Impfstoff entwickelt wurde, sank die Aktie wieder.
Wie gesagt, ich denke die " Kleinen" werden einen Vervielfacher hinlegen. Roche kannst du für den grösseren Teil des Vermögens brauchen. (Wenig Risiko, einfach sein lassen, die steigen auch so - und ne prima Dividende gibts auch) - Roche ist viel zu gross - für die ist Tamiflu nur ein Nebengleis - einen Vervielfacher wird die Aktie nicht hinlegen.
PS: Sinovac ist zudem auch ohne Vogelgrippe höchst spannend!
Grüsse
notebook
Dein Hinweis ist berechtigt. Ich denke aber, dass bei einem Hype die " Kleinen" immer am stärksten profitieren. Es wird niemand mit Bestimmtheit sagen können, wer das Rennen macht. Bei SARS ist Sinovac von 0.2 auf 6 Dollar gestiegen. Als dann der wirksame Impfstoff entwickelt wurde, sank die Aktie wieder.
Wie gesagt, ich denke die " Kleinen" werden einen Vervielfacher hinlegen. Roche kannst du für den grösseren Teil des Vermögens brauchen. (Wenig Risiko, einfach sein lassen, die steigen auch so - und ne prima Dividende gibts auch) - Roche ist viel zu gross - für die ist Tamiflu nur ein Nebengleis - einen Vervielfacher wird die Aktie nicht hinlegen.
PS: Sinovac ist zudem auch ohne Vogelgrippe höchst spannend!
Grüsse
notebook
http://tinyurl.com/73ojh
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
sollte sich die vogelgrippe ausbreiten und auf den menschen
übertragen, dann braucht ihr euch wohl keine gedanken mehr
über eure aktien zu machen. die frage ist nämlich ob ihr
das überlebt. deswegen finde ich eure diskussionen schon
pervers. millionen menschen werden sterben und einige
wenige von euch haben vielleicht etwas kohle gemacht.
bei einigen muss die börsensucht schon weit fortgeschritten und das gehirn ausgschaltet sein, oder
übertragen, dann braucht ihr euch wohl keine gedanken mehr
über eure aktien zu machen. die frage ist nämlich ob ihr
das überlebt. deswegen finde ich eure diskussionen schon
pervers. millionen menschen werden sterben und einige
wenige von euch haben vielleicht etwas kohle gemacht.
bei einigen muss die börsensucht schon weit fortgeschritten und das gehirn ausgschaltet sein, oder
Du hast Recht. Es ist eine markabre Diskussion.
Vergiss aber Folgendes nicht:
Jeder Krieg, jeder Zunami und auch Katrina haben nachträglich immer einen positiven Effekt aufs BIP - und auch auf die Börse, weil dann eine Wachstumsphase folgt.
Bei Katrina starben viele Menschen - trotzdem verdienen jetzt gerade einige am Solarboom, weil solche Umweltkatastrophen das Ökobewusstsein steigern.
Und was Sinovac und die Vogelgrippe betrifft - ja du hast Recht. Vermutlich reichen schon Gerüchte und erste Verdachtsfälle und die Wirtschaft droht zumindest kurzfristig zu erliegen. Und es könnten viele sterben. Trotzdem - wenn niemand investiert hätte und würde, gäbe es auch nie Impfstoffe. Und wenn nach Kriegen und Umweltkatastrophen niemand investieren würde, gäbe es auch keinen Aufschwung.
Du hast absolut Recht - bist du in deiner Haltung aber auch konsequent? Wir leben in einer Industrienation. Hast du dir nicht auch schon überlegt, ob wir vielleicht von Ländern, denen es nicht so gut geht, profitieren?
Mit Doppelmoral und Weglaufen ist niemandem geholfen. Und die Welt wird so auch nicht besser. Wenigstens ist sich die Börsenwelt der Bedrohung bewusst, wenn schon die Politiker das Thema ignorieren.
Vergiss aber Folgendes nicht:
Jeder Krieg, jeder Zunami und auch Katrina haben nachträglich immer einen positiven Effekt aufs BIP - und auch auf die Börse, weil dann eine Wachstumsphase folgt.
Bei Katrina starben viele Menschen - trotzdem verdienen jetzt gerade einige am Solarboom, weil solche Umweltkatastrophen das Ökobewusstsein steigern.
Und was Sinovac und die Vogelgrippe betrifft - ja du hast Recht. Vermutlich reichen schon Gerüchte und erste Verdachtsfälle und die Wirtschaft droht zumindest kurzfristig zu erliegen. Und es könnten viele sterben. Trotzdem - wenn niemand investiert hätte und würde, gäbe es auch nie Impfstoffe. Und wenn nach Kriegen und Umweltkatastrophen niemand investieren würde, gäbe es auch keinen Aufschwung.
Du hast absolut Recht - bist du in deiner Haltung aber auch konsequent? Wir leben in einer Industrienation. Hast du dir nicht auch schon überlegt, ob wir vielleicht von Ländern, denen es nicht so gut geht, profitieren?
Mit Doppelmoral und Weglaufen ist niemandem geholfen. Und die Welt wird so auch nicht besser. Wenigstens ist sich die Börsenwelt der Bedrohung bewusst, wenn schon die Politiker das Thema ignorieren.
an notebook
ich will auf keinen fall als moralapostel auftreten und
weglaufen würde ich erst recht nicht.
wer in diese oder eine andere firma investiert wartet
meines erachtens nur auf die vogelgrippe, sonst würde
er ja kein geld in die firma investieren.
auf die paar kröten die ihr investiert ist keine firma
angewiesen, da spielen genug big player mit.
bin auch ein zocker, wie du.
aber alles hat seine grenzen.
genug der worte, jeder soll selbst entscheiden was er
tut, wollte nur einen denkanstoss geben.
gruss an alle.
ich will auf keinen fall als moralapostel auftreten und
weglaufen würde ich erst recht nicht.
wer in diese oder eine andere firma investiert wartet
meines erachtens nur auf die vogelgrippe, sonst würde
er ja kein geld in die firma investieren.
auf die paar kröten die ihr investiert ist keine firma
angewiesen, da spielen genug big player mit.
bin auch ein zocker, wie du.
aber alles hat seine grenzen.
genug der worte, jeder soll selbst entscheiden was er
tut, wollte nur einen denkanstoss geben.
gruss an alle.
@rainmann
"Will auf keinen fall als moralapostel auftreten". Genau das tust du. Und ob du es zugibst oder nicht - auch du berücksichtigst die Vogelgrippe in deinen Investments. Und sei es nur dadurch, dass du deine Aktien bei einem Ausbruch der Vogelgrippe verkaufen wirst.
Und dass Sinovac auf unser Geld nicht angewiesen ist, stimmt auch nicht. Das ist ja der Sinn einer Aktiengesellschaft. Ursprünglich wurde die Rechtsform der AG geschaffen, um grössere Projekte wie bsp. den Eisenbahnbau usw... finanzieren zu können. Wenn jeder denken würde, ich investiere nicht, dann gibt es auch keine Impfstoffe.
Ist wie bei der Demokratie - wenn niemand abstimmen geht, dann gibts auch keine Demokratie. Hinter deiner Haltung versteckt sich eine sehr egoistische Haltung. (Meine Meinung).
Grüsse
notebook
"Will auf keinen fall als moralapostel auftreten". Genau das tust du. Und ob du es zugibst oder nicht - auch du berücksichtigst die Vogelgrippe in deinen Investments. Und sei es nur dadurch, dass du deine Aktien bei einem Ausbruch der Vogelgrippe verkaufen wirst.
Und dass Sinovac auf unser Geld nicht angewiesen ist, stimmt auch nicht. Das ist ja der Sinn einer Aktiengesellschaft. Ursprünglich wurde die Rechtsform der AG geschaffen, um grössere Projekte wie bsp. den Eisenbahnbau usw... finanzieren zu können. Wenn jeder denken würde, ich investiere nicht, dann gibt es auch keine Impfstoffe.
Ist wie bei der Demokratie - wenn niemand abstimmen geht, dann gibts auch keine Demokratie. Hinter deiner Haltung versteckt sich eine sehr egoistische Haltung. (Meine Meinung).
Grüsse
notebook
Gruss an alle
http://www.recombinomics.com/News/09120501/H5N1_Indonesia_Mo…
Minimal H5N1 Monitoring in Jakarta Indonesia Raises Concerns
Recombinomics Commentary
September 12, 2005
Despite the WHO recommendation, the government conducted only a minor cull in Legok area in Tangerang, following the death of Iwan and his two children. Only 31 pigs and 40 ducks confirmed to be infected with avian influenza were slaughtered.
The above comments describe the limited culling by Indonesia after the deaths of 3 family members in Tangerang. Indonesia filed an OIE report in August showing that H5N1 infections were widespread in the area. This was demonstrated even though testing was very limited. In the victim`s neighboring village of Dandang, negative data was reported for 3 chickens. However 1 of 2 fecal samples from the birdcage across the street was positive. Positive PCR data was also reported for 10 pigs and 10 ducks in Rancha Luh village in the Panongan sub-district of Tangerang. 15 PCR positive ducks were also found in another sub-district, Legok. As noted above, culling in that district was limited (the OIE report cited higher numbers, 32 pigs and 192 ducks, but also acknowledge that the culled animals only represented partial stamping out).
The current fatality is from the same suburban area southwest of Jakarta. The proximity of the most recent case and the limited testing and stamping out of infected birds and pigs raises serious doubts about the extent and effectiveness of monitoring human populations. Thus far all lab confirmed cases have been fatal, and a clear cut source of the infections has yet to be identified.
As birds begin to migrate into the area (see map), the potential for more dual infections and recombination is increased. The failure of Indonesia to seriously address this bird flu problem could mushroom into an international issue because of the urban nature of the Tangerang / Jakarta area and proximity to international airports.
Minimal H5N1 Monitoring in Jakarta Indonesia Raises Concerns
Recombinomics Commentary
September 12, 2005
Despite the WHO recommendation, the government conducted only a minor cull in Legok area in Tangerang, following the death of Iwan and his two children. Only 31 pigs and 40 ducks confirmed to be infected with avian influenza were slaughtered.
The above comments describe the limited culling by Indonesia after the deaths of 3 family members in Tangerang. Indonesia filed an OIE report in August showing that H5N1 infections were widespread in the area. This was demonstrated even though testing was very limited. In the victim`s neighboring village of Dandang, negative data was reported for 3 chickens. However 1 of 2 fecal samples from the birdcage across the street was positive. Positive PCR data was also reported for 10 pigs and 10 ducks in Rancha Luh village in the Panongan sub-district of Tangerang. 15 PCR positive ducks were also found in another sub-district, Legok. As noted above, culling in that district was limited (the OIE report cited higher numbers, 32 pigs and 192 ducks, but also acknowledge that the culled animals only represented partial stamping out).
The current fatality is from the same suburban area southwest of Jakarta. The proximity of the most recent case and the limited testing and stamping out of infected birds and pigs raises serious doubts about the extent and effectiveness of monitoring human populations. Thus far all lab confirmed cases have been fatal, and a clear cut source of the infections has yet to be identified.
As birds begin to migrate into the area (see map), the potential for more dual infections and recombination is increased. The failure of Indonesia to seriously address this bird flu problem could mushroom into an international issue because of the urban nature of the Tangerang / Jakarta area and proximity to international airports.
http://www.recombinomics.com/News/09120502/H5N1_Indonesia_Im…
H5N1 Fatality Was Immigration Agent in Jakarta Indonesia
Recombinomics Commentary
September 12, 2005
The woman was an immigration agent and dealt with many expatriates. Inquiries so far had found that people she had contact with were healthy, Mrs Siti said.
Unlike most bird flu victims, she rarely had contact with animals, but reportedly lived near a chicken slaughterhouse.....
Dr Bjorge said there was no evidence of the virus mutating to one that could easily pass between humans, but results of tests on the latest victim were yet to be received from a specialist laboratory in Hong Kong.
"We won`t know until we sequence the virus," he said. "Because there have been so few cases there is certainly no clinical data or evidence on the course of the virus in humans … there are many things we still don`t understand about the progress of this infection."
The above comments increase concerns over the latest H5N1 bird flu case in Indonesia. Like the earlier three cases, the index case is in a metropolitan area. Jakarta is adjacent to Tangerang and all of the cases appear to be southwest of the center of Jakarta. Sequence data would help determine the relationship of the human sequences to those found in Indonesia and in other human cases in Vietnam. Thailand, and Cambodia.
H5N1 has been declared to be endemic in all regions where there have been reported human cases, but Indonesian cases have all been urban in people that have little contact with poultry. The familial cluster was in a family from suburban Tangerang. The head of the household was an auditor who worked in government.
The latest case is another government office worker. These case raise questions about human-to-human spread. In other countries, most victims are farmers. If the H5N1 is coming from poultry or swine, it seems likely that there would be human rural cases. None have been reported suggesting the origin of infection in Indonesia is different, or rural cases are not being reported.
Indonesian surveillance has been lacking and government responses have lacked transparency. After the earlier outbreak, the government announced that there was no pathological evidence for bird flu and the cause of death was bacterial pneumonia. The story changed with the H5N1 positive lab data, but that would not affect the original announcement that the pathology was inconsistent with bird flu. Similarly, the bimodal distribution of onset dates strongly suggests the H5N1 was passed human-to-human, in spite of government denials, which persist today.
In the Indonesian OIE report, the number of animals tested was extremely low. However, even with limited testing, H5N1 was found in a pet birdcage across the street from the family of the index cases as well as in poultry and swine in nearby sub-sections of Tangerang. The positive results support the endemic nature of H5N1 in the Tangerang / Jakarta area, yet culling was extremely limited.
The announce of no H5N1 in a 100 meter radius of the house of the index case again raises questions about Indonesian investigative approaches, which have yet to report a cause for the earlier cluster.
The continued reporting of fatal cases in government workers who live and work in urban settings is cause for concern, as is the surveillance and investigative approaches of Indonesia.
H5N1 Fatality Was Immigration Agent in Jakarta Indonesia
Recombinomics Commentary
September 12, 2005
The woman was an immigration agent and dealt with many expatriates. Inquiries so far had found that people she had contact with were healthy, Mrs Siti said.
Unlike most bird flu victims, she rarely had contact with animals, but reportedly lived near a chicken slaughterhouse.....
Dr Bjorge said there was no evidence of the virus mutating to one that could easily pass between humans, but results of tests on the latest victim were yet to be received from a specialist laboratory in Hong Kong.
"We won`t know until we sequence the virus," he said. "Because there have been so few cases there is certainly no clinical data or evidence on the course of the virus in humans … there are many things we still don`t understand about the progress of this infection."
The above comments increase concerns over the latest H5N1 bird flu case in Indonesia. Like the earlier three cases, the index case is in a metropolitan area. Jakarta is adjacent to Tangerang and all of the cases appear to be southwest of the center of Jakarta. Sequence data would help determine the relationship of the human sequences to those found in Indonesia and in other human cases in Vietnam. Thailand, and Cambodia.
H5N1 has been declared to be endemic in all regions where there have been reported human cases, but Indonesian cases have all been urban in people that have little contact with poultry. The familial cluster was in a family from suburban Tangerang. The head of the household was an auditor who worked in government.
The latest case is another government office worker. These case raise questions about human-to-human spread. In other countries, most victims are farmers. If the H5N1 is coming from poultry or swine, it seems likely that there would be human rural cases. None have been reported suggesting the origin of infection in Indonesia is different, or rural cases are not being reported.
Indonesian surveillance has been lacking and government responses have lacked transparency. After the earlier outbreak, the government announced that there was no pathological evidence for bird flu and the cause of death was bacterial pneumonia. The story changed with the H5N1 positive lab data, but that would not affect the original announcement that the pathology was inconsistent with bird flu. Similarly, the bimodal distribution of onset dates strongly suggests the H5N1 was passed human-to-human, in spite of government denials, which persist today.
In the Indonesian OIE report, the number of animals tested was extremely low. However, even with limited testing, H5N1 was found in a pet birdcage across the street from the family of the index cases as well as in poultry and swine in nearby sub-sections of Tangerang. The positive results support the endemic nature of H5N1 in the Tangerang / Jakarta area, yet culling was extremely limited.
The announce of no H5N1 in a 100 meter radius of the house of the index case again raises questions about Indonesian investigative approaches, which have yet to report a cause for the earlier cluster.
The continued reporting of fatal cases in government workers who live and work in urban settings is cause for concern, as is the surveillance and investigative approaches of Indonesia.
SINOVAC BIOTECH LTD
Daily Commentary
Our system posted a BUY CONFIRMED today. The previous SELL recommendation that was confirmed was made on 08.30.2005 (14) days ago, when the stock price was 3.6000. Since then SVA has gained 3.06% .
Were you eager to go long? Well, without doubt, it was the right time to do so. The BUY signal was finally confirmed, and most probably you have called your broker and placed your long orders with no hesitation.
http://www.americanbulls.com/StockPage.asp?CompanyTicker=SVA…
Daily Commentary
Our system posted a BUY CONFIRMED today. The previous SELL recommendation that was confirmed was made on 08.30.2005 (14) days ago, when the stock price was 3.6000. Since then SVA has gained 3.06% .
Were you eager to go long? Well, without doubt, it was the right time to do so. The BUY signal was finally confirmed, and most probably you have called your broker and placed your long orders with no hesitation.
http://www.americanbulls.com/StockPage.asp?CompanyTicker=SVA…
Vogelgrippe könnte bis nach Europa kommen
Nach Ansicht der Vereinten Nationen könnte sich die Vogelgrippe über das Kaspische Meer und die Balkanstaaten bis nach Zentraleuropa ausbreiten. Da das Vogelgrippe-Virus vom Subtyp H5N1 bereits in Sibirien aufgetaucht ist, besteht die Gefahr, dass es wild lebende Wasservögel von dort weiter nach Südosteuropa tragen, teilte die UN-Ernährungs- und Landwirtschaftsorganisation (FAO) mit. Der auch für den Menschen gefährliche Erreger ist unter Vögeln hoch ansteckend. Unter normalen Umständen erfolgt aber keine Übertragung von Mensch zu Mensch.
"Die FAO ist besorgt, dass arme Länder in Südosteuropa, wo sich die aus Asien kommenden Zugvögel mit denen aus Nordeuropa vereinen, nicht die nötigen Mittel haben, um das Virus zu identifizieren und eine explodierende Vogelgrippe-Epidemie anzugehen", so der Leiter der Abteilung für Tiergesundheit, Joseph Domenech. Deshalb rief die UN-Organisation die Geberländer zu Spenden für vorbeugende Maßnahmen auf.
Nach Ansicht der Vereinten Nationen könnte sich die Vogelgrippe über das Kaspische Meer und die Balkanstaaten bis nach Zentraleuropa ausbreiten. Da das Vogelgrippe-Virus vom Subtyp H5N1 bereits in Sibirien aufgetaucht ist, besteht die Gefahr, dass es wild lebende Wasservögel von dort weiter nach Südosteuropa tragen, teilte die UN-Ernährungs- und Landwirtschaftsorganisation (FAO) mit. Der auch für den Menschen gefährliche Erreger ist unter Vögeln hoch ansteckend. Unter normalen Umständen erfolgt aber keine Übertragung von Mensch zu Mensch.
"Die FAO ist besorgt, dass arme Länder in Südosteuropa, wo sich die aus Asien kommenden Zugvögel mit denen aus Nordeuropa vereinen, nicht die nötigen Mittel haben, um das Virus zu identifizieren und eine explodierende Vogelgrippe-Epidemie anzugehen", so der Leiter der Abteilung für Tiergesundheit, Joseph Domenech. Deshalb rief die UN-Organisation die Geberländer zu Spenden für vorbeugende Maßnahmen auf.
must be vaccined for HEP-A. That´s an order by law. SVA will be the greatest profiteur from this school vaccine regulation.
SVA has made a delivery contract with the chinese gouvernment about the vaccines they need to do this.
And don´t forget: SVA is a solid invest which will generate lots of money in the next time but an outbreak of avian flu in china or their neighbours and SVA is skyrocketing.
SVA has made a delivery contract with the chinese gouvernment about the vaccines they need to do this.
And don´t forget: SVA is a solid invest which will generate lots of money in the next time but an outbreak of avian flu in china or their neighbours and SVA is skyrocketing.
Sinovac Biotech, Ltd (SVA), specializes in the research, development, commercialization, and sale of human vaccines for infectious illnesses, such as Hepatitis A and Hepatitis B, influenza, and SARS in China and internationally. The company has three vaccines that have completed three phases of clinical trials: Hepatitis A, Hepatitis A&B combined, and influenza (flu).
We`ve had this important news a few days ago: Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
The market cap is just about $140M.
We have a company already producing 2 vaccines for the Chinese market and with another powerful one approved. I see plenty of room for speculation here. I can say SVA is exactly the kind of stock that I want now.
Looking at the long term chart we find that SVA has recently broken a long term descending trendline, so the market is recognizing the value of this company:
On a shorter term view, we see two powerful white candles with outstanding volume:
I`m buying SVA at today`s open.
We`ve had this important news a few days ago: Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
The market cap is just about $140M.
We have a company already producing 2 vaccines for the Chinese market and with another powerful one approved. I see plenty of room for speculation here. I can say SVA is exactly the kind of stock that I want now.
Looking at the long term chart we find that SVA has recently broken a long term descending trendline, so the market is recognizing the value of this company:
On a shorter term view, we see two powerful white candles with outstanding volume:
I`m buying SVA at today`s open.
Hi, David!
I think SVA is an excellent selection for your portfolio.
I`ve been an SVA shareholder since the equity was OTC listed as
"SNYBF.OB". I accumulated most of my current position during its retracement into the 2`s this past Spring..
It doesn`t surprise me at all that SVA is filling the gap left in the $3.20-$3.30 range.
It`s semi-annual statement should be out very shortly, and will show that the company got a slow start this year with its "Bilive(R)" sales (the HepA/B vaccine), due to changes in the
Chinese vaccine distribution regulations last Spring.
L-T, the outlook for SVA is excellent. It should pick up in the Fall and Winter, and sales should be in the neigborhood of 10 million USD for 2005.
The IR firm of the company is excellent- hardworking, and not given to the hyperbole
which characterizes many Chinese equities.
My Chinese equity positions are: SVA, JST and a very recent position-HRBN.OB. All of these are modest positions, although SVA- in which I hold XX,000 shares- less so.
What will drive each of these companies` PPS are revenue growth.
My goal for SVA is multi-year growth.
http://www.3stocksonfire.com/trading/index.php?topic=2469.0
I think SVA is an excellent selection for your portfolio.
I`ve been an SVA shareholder since the equity was OTC listed as
"SNYBF.OB". I accumulated most of my current position during its retracement into the 2`s this past Spring..
It doesn`t surprise me at all that SVA is filling the gap left in the $3.20-$3.30 range.
It`s semi-annual statement should be out very shortly, and will show that the company got a slow start this year with its "Bilive(R)" sales (the HepA/B vaccine), due to changes in the
Chinese vaccine distribution regulations last Spring.
L-T, the outlook for SVA is excellent. It should pick up in the Fall and Winter, and sales should be in the neigborhood of 10 million USD for 2005.
The IR firm of the company is excellent- hardworking, and not given to the hyperbole
which characterizes many Chinese equities.
My Chinese equity positions are: SVA, JST and a very recent position-HRBN.OB. All of these are modest positions, although SVA- in which I hold XX,000 shares- less so.
What will drive each of these companies` PPS are revenue growth.
My goal for SVA is multi-year growth.
http://www.3stocksonfire.com/trading/index.php?topic=2469.0
In den Ami-Boards ist die Stimmung absolut heiss, was Sinovac betrifft.
http://www.3stocksonfire.com/trading/index.php?topic=2469.0
http://www.3stocksonfire.com/trading/index.php?topic=2469.0
3stocksonfire, ein Amiboard hat Sinovac ins Portfolio aufgenommen!
3stocksonfire, ein Amiboard hat Sinovac ins Portfolio aufgenommen!
A must be vaccined for HEP-A. That´s an order by law . SVA will be the greatest profiteur from this school vaccine regulation. SVA has made a delivery contract with the chinese gouvernment about the vaccines they need to do this. And don´t forget: SVA is a solid invest which will generate lots of money in the next time but an outbreak of avian flu in china or their neighbours and SVA is skyrocketing.
school vaccine regulation.
It doesn`t surprise me at all that SVA is filling the gap left in the $3.20-$3.30 range. It`s semi-annual statement should be out very shortly , and will show that the company got a slow start this year with its " Bilive(R)" sales (the HepA/B vaccine), due to changes in the Chinese vaccine distribution regulations last Spring.
Einfach nochmal zur Untermauerung: It`s semi-annual statement should be out very shortly[/B]
Was glaubt ihr wohl, weshalb der Kurs in letzter Zeit so beständig gestiegen ist?
Einfach nochmal zur Untermauerung: It`s semi-annual statement should be out very shortly[/B]
Was glaubt ihr wohl, weshalb der Kurs in letzter Zeit so beständig gestiegen ist?
school vaccine regulation.
Es geht nicht um die Vogelgrippe. Sinovac profitiert von staatlich vorgeschribenen Impfstoffen!!! Die Vogelgrippe würde lediglich einen zusätzlichen Hype auslösen. Hoffen wir, dass dies nie passieren wird. Aber weltweite Experten sind sich einig, die Vogelgrippe-Pandemie wird kommen. Laut Experten ist die Frage nicht ob, sondern wann. Hoffnung ist ein Wort, dass an der Börse nichts verloren hat. Man stellt Fakten zusammen, analysiert und berechnet.
Und gemäss der WHO (Weltgesundheitsorganisation) wird die Vogelgrippe-Pandemie kommen!
Es geht nicht um die Vogelgrippe. Sinovac profitiert von staatlich vorgeschribenen Impfstoffen!!! Die Vogelgrippe würde lediglich einen zusätzlichen Hype auslösen. Hoffen wir, dass dies nie passieren wird. Aber weltweite Experten sind sich einig, die Vogelgrippe-Pandemie wird kommen. Laut Experten ist die Frage nicht ob, sondern wann. Hoffnung ist ein Wort, dass an der Börse nichts verloren hat. Man stellt Fakten zusammen, analysiert und berechnet.
Und gemäss der WHO (Weltgesundheitsorganisation) wird die Vogelgrippe-Pandemie kommen!
http://www.vogelruf.de/index.php?option=com_content&task=vie…
Experten warnen vor globaler Vogelgrippe Pandemie
Forscher warnen vor Vogelgrippe PandemieBei einem Wissenschaftsgipfel in Malaysia haben Wissenschafter gewarnt, dass die Welt bei der Bekämpfung der Vogelgrippe an einem entscheidenden Punkt angelangt ist. Sie fordern die reichen Nationen dazu auf, die von der Vogelgrippe betroffenen Länder finanziell zu unterstützen, um eine globale Pandemie zu verhindern. Der Schwerpunkt der Konferenz liegt auf dem Schutz von Farm- und Marktmitarbeitern sowie der Vorbereitung von Medizinern und Veterinären auf einen Ausbruch.
Die WHO fordert eine Strategie gegen das Übergreifen des Virus von Tieren auf den Menschen und die Schaffung eines hybriden Grippeerregers. An dem Treffen nehmen Vertreter der WHO, der World Organisation for Animal Health und der Food and Agriculture Organisation of the United Nations teil.
Die Wissenschafter betonen, dass noch immer verhindert werden kann, dass das Vogelgrippe-Virus sich in eine beim Menschen ausbreitende Form verwandelt. Bei Nachfragen wird laut BBC jedoch klar, dass sie ernsthafte Bedenken haben, dass dieser Kampf bereits verloren sein könnte. Laut der WHO tun die Länder Ostasiens ihr Möglichstes um die Ausbrüche bei Geflügel und Populationen wilder Vögel in Grenzen zu halten. Ohne die finanzielle Unterstützung des Westens und seine Ressourcen haben sie jedoch laut WHO keine Chance. Der WHO-Sprecher Peter Cordingley erklärte, dass die reichen Nationen apathisch erscheinen. Er warnt davor, dass die Auswirkungen einer Vogelgrippepandemie beim Menschen deutlich größer sein würden als vor zwei Jahren bei Sars. "Wir wissen nicht, wie hoch die Zahl der Todesopfer sein wird. Wir können nur von sehr hohen Zahlen ausgehen." Es sei mit einer enormen wirtschaftlichen Dislokation zu rechnen. Aktienmärkte würden schließen, der internationale Reiseverkehr und der internationale Handel würden eingeschränkt.
Experten hoffen, dass durch die Förderung besserer hygienischer Bedingungen und sicherer Arbeitspraktiken verhindert werden kann, dass manche Tierviren die Gattungsgrenzen überschreiten. Bisher hat die Vogelgrippe in China, Vietnam und Thailand 55 Todesopfer gefordert. Infiziert das Virus eine Person, die den menschlichen Grippevirus in sich trägt, befürchten die Wissenschafter das Entstehen einer hybriden Virusform. Die Folge wäre laut WHO fast sicher eine weltweite Grippepandemie. Die Organisatoren der Konferenz hoffen, dass ein Ausbruch verzögert werden kann. Damit würde die Chance auf die Entwicklung eines wirksamen Impfstoffes steigen.
Experten warnen vor globaler Vogelgrippe Pandemie
Forscher warnen vor Vogelgrippe PandemieBei einem Wissenschaftsgipfel in Malaysia haben Wissenschafter gewarnt, dass die Welt bei der Bekämpfung der Vogelgrippe an einem entscheidenden Punkt angelangt ist. Sie fordern die reichen Nationen dazu auf, die von der Vogelgrippe betroffenen Länder finanziell zu unterstützen, um eine globale Pandemie zu verhindern. Der Schwerpunkt der Konferenz liegt auf dem Schutz von Farm- und Marktmitarbeitern sowie der Vorbereitung von Medizinern und Veterinären auf einen Ausbruch.
Die WHO fordert eine Strategie gegen das Übergreifen des Virus von Tieren auf den Menschen und die Schaffung eines hybriden Grippeerregers. An dem Treffen nehmen Vertreter der WHO, der World Organisation for Animal Health und der Food and Agriculture Organisation of the United Nations teil.
Die Wissenschafter betonen, dass noch immer verhindert werden kann, dass das Vogelgrippe-Virus sich in eine beim Menschen ausbreitende Form verwandelt. Bei Nachfragen wird laut BBC jedoch klar, dass sie ernsthafte Bedenken haben, dass dieser Kampf bereits verloren sein könnte. Laut der WHO tun die Länder Ostasiens ihr Möglichstes um die Ausbrüche bei Geflügel und Populationen wilder Vögel in Grenzen zu halten. Ohne die finanzielle Unterstützung des Westens und seine Ressourcen haben sie jedoch laut WHO keine Chance. Der WHO-Sprecher Peter Cordingley erklärte, dass die reichen Nationen apathisch erscheinen. Er warnt davor, dass die Auswirkungen einer Vogelgrippepandemie beim Menschen deutlich größer sein würden als vor zwei Jahren bei Sars. "Wir wissen nicht, wie hoch die Zahl der Todesopfer sein wird. Wir können nur von sehr hohen Zahlen ausgehen." Es sei mit einer enormen wirtschaftlichen Dislokation zu rechnen. Aktienmärkte würden schließen, der internationale Reiseverkehr und der internationale Handel würden eingeschränkt.
Experten hoffen, dass durch die Förderung besserer hygienischer Bedingungen und sicherer Arbeitspraktiken verhindert werden kann, dass manche Tierviren die Gattungsgrenzen überschreiten. Bisher hat die Vogelgrippe in China, Vietnam und Thailand 55 Todesopfer gefordert. Infiziert das Virus eine Person, die den menschlichen Grippevirus in sich trägt, befürchten die Wissenschafter das Entstehen einer hybriden Virusform. Die Folge wäre laut WHO fast sicher eine weltweite Grippepandemie. Die Organisatoren der Konferenz hoffen, dass ein Ausbruch verzögert werden kann. Damit würde die Chance auf die Entwicklung eines wirksamen Impfstoffes steigen.
http://tinyurl.com/73ojh
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
- DAS VOGELGRIPPE-VIRUS EXISTIERT NOCH NICHT IN DER FORM, DASS ES SICH RASCH VON MENSCH ZU MENSCH AUSBREITET - EXPERTEN GEHEN ABER DAVON AUS, DASS SICH DAS VIRUS MIT DEM GRIPPEVIRUS VERBINDET - SINOVAC WAR DIE ERSTE FIRMA, WELCHE EINEN IMPFSTOFF GEGEN SARS ENTWICKELTE - SINOVAC WIRD AUCH DIE ERSTE FIRMA SEIN, WELCHE EINEN IMPFSTOFF GEGEN DAS MUTIERTE VOGELGRIPPEVIRUS AUF DEN MARKT BRINGT !
http://tinyurl.com/dr67h
http://tinyurl.com/dr67h
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, " this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. " bird flu" ). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE " SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, " this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. " bird flu" ). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE " SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Chart-Analyst: Bullish Signals
MACD generates bullish signals:
1. Positive divergence
2. Bullish moving average crossover
3. Bullish centerline crossover
http://tinyurl.com/aacqc Hinweis: Ende 2003 Ausbruch SARS!
MACD generates bullish signals:
1. Positive divergence
2. Bullish moving average crossover
3. Bullish centerline crossover
http://tinyurl.com/aacqc Hinweis: Ende 2003 Ausbruch SARS!
ANGANG 2003 AUSBRUCH SARS - WIEDERHOLT SICH DAS SZENARIO MIT DER VOGELGRIPPE?
http://tinyurl.com/2ulu2
http://tinyurl.com/2ulu2
http://tinyurl.com/73ojh
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and invest
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and invest
- DAS VOGELGRIPPE-VIRUS EXISTIERT NOCH NICHT IN DER FORM, DASS ES SICH RASCH VON MENSCH ZU MENSCH AUSBREITET - EXPERTEN GEHEN ABER DAVON AUS, DASS SICH DAS VIRUS MIT DEM GRIPPEVIRUS VERBINDET - SINOVAC WAR DIE ERSTE FIRMA, WELCHE EINEN IMPFSTOFF GEGEN SARS ENTWICKELTE - SINOVAC WIRD AUCH DIE ERSTE FIRMA SEIN, WELCHE EINEN IMPFSTOFF GEGEN DAS MUTIERTE VOGELGRIPPEVIRUS AUF DEN MARKT BRINGT !
http://tinyurl.com/dr67h
http://tinyurl.com/dr67h
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, " this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. " bird flu" ). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE " SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, " this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. " bird flu" ). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE " SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Chart-Analyst: Bullish Signals
MACD generates bullish signals:
1. Positive divergence
2. Bullish moving average crossover
3. Bullish centerline crossover
http://tinyurl.com/aacqc Hinweis: Ende 2003 Ausbruch SARS!
MACD generates bullish signals:
1. Positive divergence
2. Bullish moving average crossover
3. Bullish centerline crossover
http://tinyurl.com/aacqc Hinweis: Ende 2003 Ausbruch SARS!
ANFANG 2003 AUSBRUCH SARS - WIEDERHOLT SICH DAS SZENARIO MIT DER VOGELGRIPPE?
http://tinyurl.com/2ulu2
http://tinyurl.com/2ulu2
http://tinyurl.com/73ojh
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
- DAS VOGELGRIPPE-VIRUS EXISTIERT NOCH NICHT IN DER FORM, DASS ES SICH RASCH VON MENSCH ZU MENSCH AUSBREITET - EXPERTEN GEHEN ABER DAVON AUS, DASS SICH DAS VIRUS MIT DEM GRIPPEVIRUS VERBINDET - SINOVAC WAR DIE ERSTE FIRMA, WELCHE EINEN IMPFSTOFF GEGEN SARS ENTWICKELTE - SINOVAC WIRD AUCH DIE ERSTE FIRMA SEIN, WELCHE EINEN IMPFSTOFF GEGEN DAS MUTIERTE VOGELGRIPPEVIRUS AUF DEN MARKT BRINGT !
http://tinyurl.com/dr67h
http://tinyurl.com/dr67h
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, " this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. " bird flu" ). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE " SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, " this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. " bird flu" ). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE " SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,23 | |
| -1,00 | |
| -3,84 | |
| -1,56 | |
| -0,76 | |
| +6,69 | |
| +0,41 | |
| -2,91 | |
| -4,82 | |
| -1,57 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 240 | ||
| 98 | ||
| 81 | ||
| 78 | ||
| 75 | ||
| 53 | ||
| 41 | ||
| 38 | ||
| 36 | ||
| 33 |
18.01.24 · Business Wire (dt.) · Sinovac Biotech |
11.09.23 · Business Wire (dt.) · Sinovac Biotech |
05.09.23 · Business Wire (dt.) · Sinovac Biotech |
29.08.23 · Business Wire (dt.) · Sinovac Biotech |
28.08.23 · Business Wire (dt.) · Sinovac Biotech |